Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as a tablet for oral use. It treats hypertension and heart failure, including post‑myocardial infarction, in adult patients.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inspra is an aldosterone antagonist used in cardiovascular conditions where excess mineralocorticoid activity contributes to disease. - Hypertension: lowers blood pressure by reducing sodium retention. - Heart failure: improves survival and reduces hospital admissions. - Post‑myocardial infarction heart failure: decreases risk of cardiovascular death. - Left ventricular dysfunction: reduces cardiovascular mortality.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Dizziness: sensation of light‑headedness. - Headache: mild to moderate cranial pain. - Fatigue: reduced energy or tiredness. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Increased serum creatinine: mild rise in renal markers.

Serious or Rare Side Effects: - Severe hyperkalaemia: potentially life‑threatening potassium excess. - Renal failure: marked decline in kidney function. - Angioedema: swelling of face, lips or airway. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus or anaphylaxis. - Severe hypotension: dangerous drop in blood pressure.

Before initiating therapy, clinicians should assess relevant clinical factors and monitor patients regularly. - Monitor serum potassium: check levels at baseline and periodically. - Assess renal function: evaluate creatinine and eGFR before and during treatment. - Use caution in diabetes: heightened risk of hyperkalaemia. - Avoid in severe hepatic impairment: limited safety data. - Contraindicated in existing hyperkalaemia: do not prescribe if potassium >5.0 mmol/L. - Store at ambient temperature: keep below 25°C, protect from moisture.

Eplerenone may interact with several drug classes; careful review is required. Major Interactions (Avoid): - ACE inhibitors: additive potassium increase. - Angiotensin II receptor blockers (ARBs): risk of hyperkalaemia. - Potassium supplements or salt substitutes: may cause dangerous potassium elevation. Moderate Interactions (Monitor Closely): - NSAIDs: can impair renal function and raise potassium. - Digoxin: altered serum levels may occur.